<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887194</url>
  </required_header>
  <id_info>
    <org_study_id>516-010</org_study_id>
    <nct_id>NCT04887194</nct_id>
  </id_info>
  <brief_title>PK Study to Assess Drug-drug Interaction Between Sitravatinib and a Cocktail of Substrates</brief_title>
  <official_title>Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction Study to Investigate the Effect of Sitravatinib on Probe Substrates Followed by Combination Treatment With Nivolumab in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 516-010 is an open-label Phase 1, drug-drug interaction study evaluating the effect of&#xD;
      sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of this study is designed to evaluate the potential for drug-drug interactions with&#xD;
      sitravatinib monotherapy when administered with probe drugs for specific cytochrome P450&#xD;
      (CYP) enzymes (CYP2C9, CYP2D6, and CYP3A4) and P-glycoprotein (P-gp) and breast cancer&#xD;
      resistance protein (BCRP) transporters&#xD;
&#xD;
      Part 2 allows for patients to continue sitravatinib treatment with the addition of the&#xD;
      checkpoint inhibitor Nivolumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Two Part, Phase enrolling patients with advanced tumor types. All patients receive the same treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of probe drugs (warfarin, dextromethorphan, midazolam, digoxin, and rosuvastatin) derived from the plasma concentration time profile before and after oral administration of sitravatinib</measure>
    <time_frame>Part 1; 1-20 Days</time_frame>
    <description>AUC from time zero to the last data point (AUC-last)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of probe drugs (warfarin, dextromethorphan, midazolam, digoxin, and rosuvastatin) derived from the plasma concentration time profile before and after oral administration of sitravatinib</measure>
    <time_frame>Part 1; 1-20 Days</time_frame>
    <description>AUC from time zero to infinity (AUCâˆž)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of probe drugs (warfarin, dextromethorphan, midazolam, digoxin, and rosuvastatin) derived from the plasma concentration time profile before and after oral administration of sitravatinib</measure>
    <time_frame>Part 1; 1-20 Days</time_frame>
    <description>C-max</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, an average of 12 months</time_frame>
    <description>Characterization of AEs by incidence, severity, timing, seriousness &amp; relationship to study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of sitravatinib and M10</measure>
    <time_frame>1-20 Days</time_frame>
    <description>C-max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of sitravatinib and M10</measure>
    <time_frame>1-20 Days</time_frame>
    <description>AUC over the dosing interval (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of sitravatinib and M10</measure>
    <time_frame>1-20 Days</time_frame>
    <description>trough plasma concentration (C-trough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of sitravatinib and M10</measure>
    <time_frame>1-20 Days</time_frame>
    <description>time to maximum concentration (t-max)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1-20 Days</time_frame>
    <description>Safety characterized by type, incidence, severity, timing, seriousness &amp; relationship to study treatment of adverse events, and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective disease response</measure>
    <time_frame>Through study completion, an average of 12 months</time_frame>
    <description>Measured in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and duration of response (DOR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the potential for drug-drug interactions (DDI) with sitravatinib monotherapy. To determine the effect of sitravatinib on the pharmacokinetics (PK) of midazolam (CYP3A4 probe substrate), warfarin (CYP2C9 probe substrate), dextromethorphan (CYP2D6 probe substrate), rosuvastatin (BCRP probe substrate), and digoxin (P-gp probe substrate).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1, Part 2 Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate safety and tolerability of Sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases</description>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <arm_group_label>Phase 1, Part 2 Combination Therapy</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>CYP2C9 probe substrate</description>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>CYP2D6 probe substrate</description>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <other_name>Robitussin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>CYP3A4 probe substrate</description>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>P-gp probe substrate</description>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <other_name>LANOXICAPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>BCRP probe substrate</description>
    <arm_group_label>Phase 1, Part 1 Drug-Drug Interaction with sitravatinib monotherapy</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a programmed death receptor (PD-1) blocking antibody</description>
    <arm_group_label>Phase 1, Part 2 Combination Therapy</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of unresectable advanced/metastatic solid tumor&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate bone marrow and organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing medical condition or need for treatment with medication that may affect the PK&#xD;
             of study treatments during Part 1&#xD;
&#xD;
          -  Immunocompromising conditions&#xD;
&#xD;
          -  Impaired heart function&#xD;
&#xD;
          -  Active or prior documented autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curtis Chin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mirati Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Ramos</last_name>
    <phone>8582815979</phone>
    <email>ramosc@mirati.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NEXT Oncology</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

